Abstract
Objective: To investigate the prevalence and diagnostic significance of antibodies against telomeric DNA in systemic lupus erythematosus (SLE) and other autoimmune rheumatic diseases, and to make comparisons with five conventional anti-DNA or anti-nuclear antibody (ANA) assays.
Methods: Antibodies to telomeres, which are highly repetitive sequences of DNA (TTAGGG/CCCTAA) at the end of eukaryotic chromosomes, were measured by an enzyme linked immunosorbent assay (ELISA) in 305 patients with SLE and 125 patients with other autoimmune rheumatic diseases (78 rheumatoid arthritis, 32 primary Sjögren's syndrome, eight mixed connective tissue disease, seven miscellaneous rheumatic diseases). Other assays used were two commercial ELISA assays for anti-dsDNA using calf thymus as antigen, Crithidialuciliae immunofluorescence, and radioimmunoassay (RIA) for anti-dsDNA and immunofluorescence using Hep-2 cells for ANA.
Results: The prevalence of anti-telomere in SLE was 60%, v 5% in rheumatoid arthritis and 18% in other autoimmune rheumatic diseases. Specificity of anti-telomere for SLE was 91%; positive and negative predictive values were 95% and 46%, respectively. For anti-dsDNA by two ELISA assays using calf thymus as antigen, sensitivities were 69% and 29% and specificities 66% and 96%, respectively. Other anti-dsDNA assays had low sensitivities (RIA 43%, Crithidia immunofluorescence 13%). The association of anti-telomere with a history of nephritis in patients with SLE was stronger (p = 0.005) than by any other assay (p = 0.006–0.999). The correlations between the different assays were good (p<0.001 for all comparisons).
Conclusions: The new ELISA for anti-telomere antibodies using standardised human dsDNA as antigen is a sensitive and highly specific test for SLE.
Full Text
The Full Text of this article is available as a PDF (82.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alarcón-Segovia D., Cardiel M. H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989 Mar;16(3):328–334. [PubMed] [Google Scholar]
- Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
- Bohan A., Peter J. B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344–347. doi: 10.1056/NEJM197502132920706. [DOI] [PubMed] [Google Scholar]
- Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Doménech I., Aydintug A. O., Jedryka-Góral A., de Ramón E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar;72(2):113–124. [PubMed] [Google Scholar]
- Derksen R. H. W. M., Bast E. J. E. G., Strooisma T., Jacobs J. W. G. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis. 2002 Dec;61(12):1099–1102. doi: 10.1136/ard.61.12.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000 Jun;53(6):424–432. doi: 10.1136/jcp.53.6.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- James K., Meek G. Evaluation of commercial enzyme immunoassays compared to immunofluorescence and double diffusion for autoantibodies associated with autoimmune diseases. Am J Clin Pathol. 1992 Apr;97(4):559–565. doi: 10.1093/ajcp/97.4.559. [DOI] [PubMed] [Google Scholar]
- Koskenmies S., Widen E., Kere J., Julkunen H. Familial systemic lupus erythematosus in Finland. J Rheumatol. 2001 Apr;28(4):758–760. [PubMed] [Google Scholar]
- Pisetsky D. S. Antibody responses to DNA in normal immunity and aberrant immunity. Clin Diagn Lab Immunol. 1998 Jan;5(1):1–6. doi: 10.1128/cdli.5.1.1-6.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reichlin M. Anti-telomere antibodies in systemic lupus erythematosus. Lupus. 2000;9(5):317–317. doi: 10.1191/096120300678828442. [DOI] [PubMed] [Google Scholar]
- Stollar B. D. Molecular analysis of anti-DNA antibodies. FASEB J. 1994 Mar 1;8(3):337–342. doi: 10.1096/fasebj.8.3.7511550. [DOI] [PubMed] [Google Scholar]
- Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
- Vitali C., Bombardieri S., Moutsopoulos H. M., Balestrieri G., Bencivelli W., Bernstein R. M., Bjerrum K. B., Braga S., Coll J., de Vita S. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993 Mar;36(3):340–347. doi: 10.1002/art.1780360309. [DOI] [PubMed] [Google Scholar]
- Wallace D. J., Salonen E. M., Avaniss-Aghajani E., Morris R., Metzger A. L., Pashinian N. Anti-telomere antibodies in systemic lupus erythematosus: a new ELISA test for anti-DNA with potential pathogenetic implications. Lupus. 2000;9(5):328–332. doi: 10.1191/096120300678828343. [DOI] [PubMed] [Google Scholar]
- Werle E., Blazek M., Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus. 1992 Dec;1(6):369–377. doi: 10.1177/096120339200100606. [DOI] [PubMed] [Google Scholar]